Clinical Trial Update: Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of bortezomib and rituximab in Waldenström's macroglobulinemia; the study is active but not recruiting, with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-05-04